{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041293","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.188337+00:00","generated_at":"2026-05-16T22:17:20.268395+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Femasys receives second $500k FemBloc order from Kebomed for Europe","bullets":["Order valued at ~$500k for commercial launch of FemBloc in France and Benelux region.","Kebomed, a leading distributor, placed the order following Femasys' recent entry into Spain.","FemBloc is a non-surgical permanent contraceptive using a patented polymer to occlude fallopian tubes.","CEO Kathy Lee-Sepsick cited strategic partnerships driving international expansion and shareholder value.","No anesthesia, incisions, or recovery time required; addresses unmet need in reproductive health."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041293","json":"https://secwatch.observer/filing/0001140361-25-041293.json","markdown":"https://secwatch.observer/filing/0001140361-25-041293.md","text":"https://secwatch.observer/filing/0001140361-25-041293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125041293/0001140361-25-041293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125041293/ef20058658_form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:17:20.268395+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}